Showing results (51-60 of 673) with videos related to
Sort By:
Pageof 68
HIV Clinical Trials|February 11, 2003
First-line therapy and mitochondrial damage: different nucleosides, different findingsFrancisco Blanco, Teresa García-Benayas, Juan José de la Cruz, et al.HIV Clinical Trials|March 15, 2017
The HIV Care Cascade and sub-analysis of those linked to but not retained in care: the experience from a tertiary HIV referral service in Dublin IrelandP McGettrick, B Ghavami-Kia, W Tinago, et al.HIV Clinical Trials|February 13, 2014
Minorities remain underrepresented in HIV/AIDS research despite access to clinical trialsJose R Castillo-Mancilla, Susan E Cohn, Supriya Krishnan, et al.HIV Clinical Trials|February 13, 2014
Durability of the first antiretroviral treatment regimen and reasons for change in patients with HIV infectionJavier De La Torre-Lima, Ana Aguilar, Jesus Santos, et al.HIV Clinical Trials|December 14, 2016
Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysisHannah Ewald, Marilia Santini-Oliveira, Julian-Emanuel Bühler, et al.HIV Clinical Trials|January 14, 2017
Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudyMaria Saumoy, Juan M Tiraboschi, Jordi Ordoñez-Llanos, et al.HIV Clinical Trials|August 14, 2003
Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adultsPeter J Ruane, David M Parenti, David M Margolis, et al.HIV Clinical Trials|October 30, 2003
Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switchL R Tomasoni, A Patroni, C Torti, et al.HIV Clinical Trials|November 25, 2003
Differences in durability of treatment with initial PI-based regimensMaria Jesús Pérez-Elías, Ana Moreno, Santiago Moreno, et al.HIV Clinical Trials|November 25, 2003
Human immunodeficiency virus: scientific challenges impeding candidate vaccinesVincent IdemyorPageof 68